Cantor Fitzgerald initiated coverage on Lineage Cell Therapeutics with a new price target

3/31/21 7:08:30 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Cantor Fitzgerald initiated coverage of Lineage Cell Therapeutics with a rating of Overweight and set a new price target of $6.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LCTX

Date	Price Target	Rating	Analyst
8/20/2024	$4.00	Buy	Craig Hallum
11/2/2022	$5.00	Outperform	Robert W. Baird
6/14/2022	$4.00	Buy	B. Riley Securities
8/19/2021	$8.00	Outperform	Noble Capital Markets